ReviewThe British journal of ophthalmology2017
Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention.
Review in The British journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Comparative efficacy of different treatment modalities in the management of macular oedema in retinitis pigmentosa: a systematic review and network meta-analysis.BMJ open ophthalmology · 2026Pooled it
- Management of Cystoid Macular Edema in Retinitis Pigmentosa: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- Management of cystoid macular edema secondary to retinitis pigmentosa via subliminal micropulse yellow laser.Lasers in medical science · 2021Trial
- Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa.The British journal of ophthalmology · 2020Trial
- Clinical and Molecular Features ofOphthalmology science · 2026Article
- Bromelain and Curcumin Oral Supplementation for Refractory Inherited Retinal Dystrophy-Related Macular Oedema: Changes in Macular Thickness and Visual Acuity over 12 Months.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Spontaneous resolution of cystoid macular edema with concurrent axial elongation in a pediatric patient with Usher syndrome type 1B: a case report.BMC ophthalmology · 2026Article
- Correlations between Spectral Domain Optical Coherence Tomography Measurements and Visual Acuity in Patients with Retinitis Pigmentosa at Baseline and One-Year Follow-Up.Ophthalmic research · 2026Article
- Detection of cystoid macular edema in patients with retinitis pigmentosa based on deep learning.International journal of retina and vitreous · 2025Article
- Article
- Review
- Validation of a deep learning model for the automated detection and quantification of cystoid macular oedema on optical coherence tomography in patients with retinitis pigmentosa.Acta ophthalmologica · 2025Article
- Article
- Cystoid Macular Edema in Non-Syndromic Retinitis Pigmentosa: Associations With Causative Genes in a Large Cohort.Investigative ophthalmology & visual science · 2025Article
- Clearing the AIR: AAmerican journal of ophthalmology case reports · 2025Article
- Optical coherence tomography analysis at initial diagnosis in patients with retinitis pigmentosa and associated cystoid macular edema.PloS one · 2025Article
- The crossroads of ocular inflammation and inherited retinal degenerations: a report of two cases.Digital journal of ophthalmology : DJO · 2025Article
- Ocular and systemic immune profiles associated with cystoid macular edema in retinitis pigmentosa.Frontiers in ophthalmology · 2025Article
- Multiple evanescent white dot syndrome and presentations similar to multiple evanescent white dot syndrome in other disorders: a narrative review.International journal of ophthalmology · 2025Review
- Case Report: A family of fluctuating cystoid macular edema caused byFrontiers in medicine · 2025Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Hereditary retinal diseases are now the leading cause of blindness certification in the working age population (age 16-64 years) in England and Wales, of which retinitis pigmentosa (RP) is the most common disorder. RP may be complicated by cystoid macular oedema (CMO), causing a reduction of central vision. The underlying pathogenesis of RP-associated CMO (RP-CMO) remains uncertain, however, several mechanisms have been proposed, including: (1) breakdown of the blood-retinal barrier, (2) failure (or dysfunction) of the pumping mechanism in the retinal pigment epithelial, (3) Müller cell oedema and dysfunction, (4) antiretinal antibodies and (5) vitreous traction. There are limited data on efficacy of treatments for RP-CMO. Treatments attempted to date include oral and topical carbonic anhydrase inhibitors, oral, topical, intravitreal and periocular steroids, topical non-steroidal anti-inflammatory medications, photocoagulation, vitrectomy with internal limiting membrane peel, oral lutein and intravitreal antivascular endothelial growth factor injections. This review summarises the evidence supporting these treatment modalities. Successful management of RP-CMO should aim to improve both quality and quantity of vision in the short term and may also slow central vision loss over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.